August 8, 2022

Patients Experience Excellent Health Outcomes from Telemedicine

Doctors and patients have come to rely on telemedicine for communication and remote health monitoring, including cardiac telemetry. Concerns about the efficacy of remote medicine have been alleviated as research shows that health outcomes are the same or better with telemedicine. Infobionic’s MoMe™ ARC Platform can deliver the next generation of remote monitoring to accommodate the growing demand for accurate, reliable telemetry technology.

(Waltham, MA) August 8, 2022—The COVID-19 pandemic accelerated the use of telemedicine for both routine and acute care. Doctors and patients quickly grew accustomed to videoconferencing and remote monitoring for conditions such as diabetes, respiratory illnesses, and chronic pain. The paradigm shift has boosted demand for better remote healthcare technology to treat a broad range of health conditions. Despite concerns about the efficacy of remote healthcare, evidence shows no downside to telehealth when used appropriately. But current hospital telemetry systems suffer from a lack of portability and adaptability. High-acuity telemetry lacks portability. Portable units lack high acuity.

“The pandemic showed doctors and patients that remote medicine doesn’t result in compromised care,” says Stuart Long, CEO of Infobionic. “The times that telemedicine falls short are when the technology can’t deliver the right information at the right time due to lack of technology to adapt to varying levels of acuity.”

A 2022 study published in the Annals of Internal Medicine reviewed 38 clinical trials from 2013 to 2021 that measured the ability of telehealth to replace or enhance regular patient care. Researchers found that in most cases, care provided by telemedicine had the same or better quality as in-person visits.1

Providers have adopted several types of telehealth:

• Virtual medical appointments using phone or video chat.
• Using secure messaging, emails, or patient portals for exchanging information. Technology to remotely track and report bio-feedback has been in use for many years.
• Use of remote monitoring devices that send feedback to health care providers. Remote cardiac telemetry is used in hospital settings and hospital-to-home situations.

InfoBionic’s MoMe™ ARC Platform* bridges the gap between portability and acuity. It’s an innovative new cloud platform that allows a flexible and modular suite of products to work in concert to capture data in from real-time to near real-time.

Their 3rd generations of products will include MoMe™ Gateway*, and a suite of innovative Bluetooth lead sets that allows greater quality, precision & flexibility from low acuity to high acuity in both inpatient and outpatient care settings. The Gateway is the 3rd generation of Bluetooth-enabled technology offered by InfoBionic that’s multicarrier compatible on 4G LTE networks. Along with supporting Bluetooth, the system also supports Wi-Fi connectivity. As part of the MoMe™ ARC Platform*, the MoMe Gateway* can also allow providers to connect to other qualified third-party Bluetooth devices in addition to the new MoMe™ K-series Lead Sets. The Gateway is designed to collect information from three different InfoBionic developed modular Bluetooth lead set systems.

The MoMe Now* is designed specifically for hospital telemetry to provide step-down level of telemetry for any bed or location that would need an easy to deploy mobile telemetry monitor. Further, it builds on our core expertise to enable a seamless hospital-to-home patient transition where continuous monitoring from real-time to near real-time is essential for meeting the demands of virtual care monitoring.

“Reliable, accurate, and flexible cardiac telemetry is the natural next step for telemedicine,” says Long. “Systems like the MoMe™ ARC Platform* allow doctors to achieve the clinical outcomes patients deserve without the technical drawbacks of older telemetry systems.”

For more information about InfoBionic, visit their website at https://infobionic.com/.

*This product has not been approved by the FDA for sale in the US.

About InfoBionic

InfoBionic’s digital technology has transformed the efficiency and economics of cardiac remote patient monitoring. The company’s MoMe™ ARC platform vision is to remove the roadblocks hindering remote diagnosis and decision-making. The Massachusetts-based team of seasoned entrepreneurs have had successful careers in healthcare, IT, medical devices, and mobile technology and bring specific expertise in remote monitoring and cardiology. Visit https://InfoBionic.com/ 

References:

1.    Annals of Internal Medicine. “Video Teleconferencing for Disease Prevention, Diagnosis, and Treatment.” February 2022.